IL139008D0 - Methods for treating neuropsychiatric disorders - Google Patents

Methods for treating neuropsychiatric disorders


Publication number
IL139008D0 IL13900899A IL13900899A IL139008D0 IL 139008 D0 IL139008 D0 IL 139008D0 IL 13900899 A IL13900899 A IL 13900899A IL 13900899 A IL13900899 A IL 13900899A IL 139008 D0 IL139008 D0 IL 139008D0
Prior art keywords
neuropsychiatric disorders
treating neuropsychiatric
Prior art date
Application number
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US8164598P priority Critical
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Priority to PCT/US1999/008056 priority patent/WO1999052519A2/en
Publication of IL139008D0 publication Critical patent/IL139008D0/en



    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/315Zinc compounds
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
IL13900899A 1998-04-14 1999-04-14 Methods for treating neuropsychiatric disorders IL139008D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US8164598P true 1998-04-14 1998-04-14
PCT/US1999/008056 WO1999052519A2 (en) 1998-04-14 1999-04-14 Methods for treating neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
IL139008D0 true IL139008D0 (en) 2001-11-25



Family Applications (1)

Application Number Title Priority Date Filing Date
IL13900899A IL139008D0 (en) 1998-04-14 1999-04-14 Methods for treating neuropsychiatric disorders

Country Status (17)

Country Link
US (5) US6228875B1 (en)
EP (3) EP2338482A3 (en)
JP (1) JP2002511409A (en)
AT (1) AT369848T (en)
AU (1) AU765603C (en)
CA (2) CA2328197C (en)
CY (1) CY1106898T1 (en)
DE (2) DE1073432T1 (en)
DK (1) DK1073432T3 (en)
ES (1) ES2164040T3 (en)
HK (1) HK1036583A1 (en)
HU (1) HU0101627A3 (en)
IL (1) IL139008D0 (en)
NZ (1) NZ508160A (en)
PT (1) PT1073432E (en)
RU (1) RU2219924C2 (en)
WO (1) WO1999052519A2 (en)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
IL139008D0 (en) * 1998-04-14 2001-11-25 Gen Hospital Corp Methods for treating neuropsychiatric disorders
TR200101082T2 (en) * 1998-10-16 2001-09-21 Janssen Pharmaceutica N.V. Consciousness or the ability to detect the developer compositions.
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
DE19918105C1 (en) * 1999-04-22 2000-09-21 Lohmann Therapie Syst Lts Transdermal patch for administering neuroleptic agent i.e. fluphenazine, flupentixol or triflupromazine, includes matrix layer containing penetration enhancer and hydrocarbon polymer
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
ES2294414T3 (en) * 2000-08-25 2008-04-01 Research Corporation Technologies, Inc Use of anticonvulsants amino acids for the treatment of migraine.
US20030119884A1 (en) * 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
US20070117869A1 (en) * 2000-11-01 2007-05-24 Cognition Pharmaceuticals Llc Methods for treating coginitive impairment and improving cognition
AU2002239464B2 (en) * 2000-11-01 2007-01-04 Cognition Pharmaceuticals Llc Methods and compositions for regulating memory consolidation
US20030232890A1 (en) * 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
US20050059743A1 (en) * 2000-11-01 2005-03-17 Sention, Inc. Methods for treating mild cognitive impairment and alzheimer's disease
US7619005B2 (en) * 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
US20020155170A1 (en) * 2000-11-30 2002-10-24 Walsh William John Nutrient supplements and methods for treating autism and for preventing the onset of autism
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US7750030B2 (en) 2001-03-29 2010-07-06 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EP1935414A3 (en) * 2001-05-02 2010-08-18 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancig learning and memory
AT411019T (en) * 2001-05-02 2008-10-15 Brni Neurosciences Inst Carbonic anhydrase activators for improving the learning and memory performance
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
AU2002360775B9 (en) 2001-12-28 2008-07-24 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
EP1475090A4 (en) * 2002-02-14 2007-08-08 Ajinomoto Kk Drugs for mitochondrial diseases
WO2003077998A1 (en) * 2002-03-15 2003-09-25 H. Lundbeck A/S Use of asc-1 inhibitors to treat neurological and psychiatric disorders
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
AU2003240746A1 (en) * 2002-06-10 2003-12-22 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
KR100446503B1 (en) * 2002-06-19 2004-09-04 삼성전자주식회사 Compound access point and method for managing voice/data packet using the access point
AU2003244205A1 (en) * 2002-07-04 2004-01-23 Mitsubishi Pharma Corporation Method of examining and diagnosing integration dysfunction syndrome
MXPA05000294A (en) * 2002-07-30 2005-08-19 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions.
FR2843590B1 (en) 2002-08-14 2007-10-05 Prestwick Scient Capital Inc Derivatives of the R (+) - 2-amino-3-hydroxypropanoic has glycinergic action
US9174975B2 (en) 2002-08-22 2015-11-03 Sumitomo Dainippon Pharma Co., Ltd Remedy for integration dysfunction syndrome
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
KR20050055781A (en) * 2002-10-25 2005-06-13 화이자 프로덕츠 인크. Novel injectable depot formulations
US7636597B2 (en) * 2002-11-14 2009-12-22 Brainsgate, Ltd. Surgical tools and techniques for stimulation
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
AR042806A1 (en) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combination of carbostyril derivatives and inhibitors of serotonin reuptake for treating mood disorders
DE60317098T2 (en) 2002-12-27 2008-08-07 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives with selective serotonin uptake inhibitors for treatment of mood disorders
US20070249537A1 (en) * 2003-01-23 2007-10-25 Supernus Pharmaceuticals, Inc. Absorption enhancing agents
IL154318A (en) 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
WO2004091601A1 (en) * 2003-04-17 2004-10-28 Jallal Messadek Floating oral formulations for controlled release of betaine
EP1633360A1 (en) * 2003-05-16 2006-03-15 Pfizer Products Incorporated Treatment of psychotic and depressive disorders
EP1625333A1 (en) 2003-05-21 2006-02-15 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
WO2004112700A2 (en) * 2003-06-06 2004-12-29 The General Hospital Corporation Methods and compositions for modulating amyloid precursor protein translation
WO2004113333A1 (en) 2003-06-23 2004-12-29 Dainippon Sumitomo Pharma Co., Ltd. Therapeutic agent for senile dementia
BE1015608A6 (en) * 2003-07-15 2005-06-07 Messadek Jallal TREATMENT arteritis.
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
WO2005016319A2 (en) * 2003-08-06 2005-02-24 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2005053703A1 (en) * 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
CN1964713A (en) * 2003-12-23 2007-05-16 达法尔摩公司 Co-administration of dopamine-receptor binding compounds
US20120225916A1 (en) * 2003-12-29 2012-09-06 Mcdevitt Jason P Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
CA2592631A1 (en) 2003-12-29 2005-07-21 Jason Mcdevitt Compositions and methods to treat recurrent medical conditions
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2005080976A1 (en) 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Method of in vivo screening of therapeutic agent for memory/learning dysfunction by schizophrenia
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050209317A1 (en) * 2004-03-22 2005-09-22 Apkarian A V Method and compositions for treatment of chronic neuropathic pain
TW200538181A (en) 2004-05-18 2005-12-01 Brni Neurosciences Inst Treatment of depressive disorders
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US20050277626A1 (en) * 2004-05-27 2005-12-15 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
AU2005259961B2 (en) * 2004-06-25 2012-05-17 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060039867A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline
US20090299418A1 (en) * 2004-08-23 2009-12-03 Brainsgate Ltd. Concurrent bilateral spg modulation
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
WO2006060186A2 (en) * 2004-11-30 2006-06-08 Bayer Pharmaceuticals Corporation Pyrazole derivatives for the treatment of dementia and related disorders
DE602005019203D1 (en) * 2004-12-16 2010-03-18 Janssen Pharmaceutica Nv inhibitor combination of a glycine transporter (GlyT1) and an antipsychotic agent for the treatment of symptoms of schizophrenia and their preparation and use
WO2006067529A1 (en) * 2004-12-21 2006-06-29 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as glyt1 inhibitors
US8163956B2 (en) 2005-06-13 2012-04-24 Merck Sharp & Dohme Corp. Inhibitors of GLYT1 transporters
WO2007006157A1 (en) * 2005-07-14 2007-01-18 The University Of British Columbia Neuroprotective modulation of nmda receptor subtype activities
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US7829120B2 (en) * 2005-09-09 2010-11-09 Labopharm Inc. Trazodone composition for once a day administration
WO2007041025A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Radiolabeled glycine transporter inhibitors
BRPI0709146A2 (en) * 2006-03-24 2011-06-28 Wyeth Corp methods for treating cognitive disorders and other disorders
WO2008013860A2 (en) * 2006-07-28 2008-01-31 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2008055341A1 (en) * 2006-11-09 2008-05-15 Centre For Addiction And Mental Health Slc1a1 antipsychotic drug response markers
WO2008118785A2 (en) * 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
US20100113453A1 (en) * 2007-04-10 2010-05-06 Mcdevitt Jason P Sublingual Formulations of D-Cycloserine and Methods of Using Same
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc Improving the tolerability of mirtazapine and a second active by using them in combination
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
IL188681D0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
EP2111858A1 (en) * 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Novel treatment for alzheimer's disease
GB0817379D0 (en) * 2008-09-23 2008-10-29 Merck Sharp & Dohme New use
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
RU2537187C2 (en) * 2009-09-14 2014-12-27 Сисейдо Компани,Лтд. Composition for reducing injury caused by uv radiation
TWI544923B (en) * 2009-12-29 2016-08-11 Ying Jui Ho Pharmaceutical compositions for treatment of neurodegenerative disorders
EP2538939A1 (en) * 2010-02-24 2013-01-02 Universität Zürich Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids
US20120041066A1 (en) * 2010-08-16 2012-02-16 Lombard Jay L Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
US8624052B2 (en) * 2010-11-12 2014-01-07 Promentis Pharmaceuticals, Inc. S-t-butyl protected cysteine di-peptide analogs and related compounds
CA2826180A1 (en) * 2011-01-31 2012-08-09 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
US20130296430A1 (en) * 2012-05-03 2013-11-07 Antonio Hardan Compositions and methods for treating autism and autism spectrum disorder
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR101499299B1 (en) * 2012-08-03 2015-03-09 연세대학교 산학협력단 Autism model mouse by Shank2 gene deletion and the use thereof
CA2881189A1 (en) * 2012-08-07 2014-02-13 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
AT514349B1 (en) * 2013-06-12 2018-05-15 Red Bull Gmbh Alpha-alkylated amino acids (AAAAs)
WO2015031493A1 (en) * 2013-08-27 2015-03-05 The Johns Hopkins University Amino acid treatment of seizures
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
AU2016303610A1 (en) * 2015-08-04 2018-02-01 Confluence Pharmaceuticals, Llc Combination therapy using acamprosate and D-cycloserine
CN105476976B (en) * 2015-12-22 2018-09-25 广州瑞尔医药科技有限公司 The pharmaceutical composition and its preparation method and application
TWI648049B (en) * 2016-05-25 2019-01-21 財團法人國家衛生研究院 Other methods for reducing the life of the k-induced psychosis-like side effects and addiction disorders and compositions
US10226442B2 (en) * 2017-07-10 2019-03-12 Syneurx International (Taiwan) Corp. Lithium salts of N-substituted glycine compounds and uses thereof
KR101952443B1 (en) * 2018-08-23 2019-02-26 주식회사 아스트로젠 Novel magnesium-serinate compound and use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873722A (en) 1974-05-31 1975-03-25 Nelson Res & Dev Method for treating schizophrenia
JPS5520747A (en) * 1978-08-01 1980-02-14 Sumitomo Chem Co Ltd Antidepressant
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US5468763A (en) 1987-12-01 1995-11-21 G. D. Searle & Co. Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
US5015740A (en) 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5260324A (en) 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US6294520B1 (en) 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
JPH03236315A (en) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd Antipsychotic agent
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
DE4117629A1 (en) 1991-05-29 1992-12-03 Max Planck Gesellschaft Use of phosphatidyl serine derivs. - for treatment of depression and loss of cerebral function e.g. Parkinson's disease and Alzheimer's disease
NO179904C (en) 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Condensed heterocyclic compounds and their use
GB9300051D0 (en) 1993-01-04 1993-03-03 Merck Sharp & Dohme Therapeutic agents
CA2160459A1 (en) * 1993-04-27 1994-11-10 Ichio Noda Serine derivative
JPH0826986A (en) * 1994-07-21 1996-01-30 Yamanouchi Pharmaceut Co Ltd Antiphencyclidine agent
RU2096044C1 (en) 1995-07-19 1997-11-20 Малое предприятие "Ветта" Veterinary implantable preparation for regulation of biological rhythm in animals
US6355681B2 (en) 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
AT320804T (en) 1995-12-07 2006-04-15 Daniel C Javitt Treatment of negative and cognitive symptoms of schizophrenia with the glycine uptake antagonists
ES2270462T3 (en) * 1996-05-31 2007-04-01 Allelix Neuroscience Inc. pharmaceutical product for the treatment of neurological and neuropsychiatric disorders.
IL139008D0 (en) * 1998-04-14 2001-11-25 Gen Hospital Corp Methods for treating neuropsychiatric disorders
NZ508169A (en) 1998-05-23 2003-10-31 Altana Pharma Ag Quinoline-aminomethyl-pyridyl derivatives with anti- helicobacter activity
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction

Also Published As

Publication number Publication date
AU765603C (en) 2004-08-05
HK1036583A1 (en) 2008-06-06
DE1073432T1 (en) 2002-02-07
DK1073432T3 (en) 2007-12-17
WO1999052519A3 (en) 1999-12-02
AU765603B2 (en) 2003-09-25
US20020193429A1 (en) 2002-12-19
CA2601132A1 (en) 1999-10-21
CA2328197A1 (en) 1999-10-21
HU0101627A2 (en) 2001-10-28
US6228875B1 (en) 2001-05-08
WO1999052519A2 (en) 1999-10-21
JP2002511409A (en) 2002-04-16
US6667297B2 (en) 2003-12-23
US20050250851A1 (en) 2005-11-10
US6420351B1 (en) 2002-07-16
AT369848T (en) 2007-09-15
NZ508160A (en) 2004-01-30
EP2338482A3 (en) 2011-12-21
EP1844769A3 (en) 2010-02-10
CA2601132C (en) 2011-11-08
US20040092530A1 (en) 2004-05-13
EP1844769A2 (en) 2007-10-17
HU0101627A3 (en) 2003-02-28
US6974821B2 (en) 2005-12-13
US20020035145A1 (en) 2002-03-21
AU3557199A (en) 1999-11-01
ES2164040T1 (en) 2002-02-16
DE69936848D1 (en) 2007-09-27
EP1073432B1 (en) 2007-08-15
ES2164040T3 (en) 2008-02-01
PT1073432E (en) 2007-10-22
DE69936848T2 (en) 2008-05-15
EP1073432A2 (en) 2001-02-07
CA2328197C (en) 2007-11-20
US7704978B2 (en) 2010-04-27
RU2219924C2 (en) 2003-12-27
CY1106898T1 (en) 2012-09-26
EP2338482A2 (en) 2011-06-29

Similar Documents

Publication Publication Date Title
GB2336693B (en) Assembly process apparatus
IL137413D0 (en) Methods and apparatus for calcification scoring
HU9700028D0 (en) Process for controlling immunofunction
EP0792371A4 (en) Combination method for acne treatment
HU0500044D0 (en) Process for prepare oxazolidinones
CZ9804278A3 (en) Anticonvulsive sulfamate derivatives suitable for treating obesity
GB9625335D0 (en) Process
GB9626429D0 (en) Process
GB9626317D0 (en) Process
GB9626428D0 (en) Process
GB9609441D0 (en) Process
AU8515901A (en) Methods for treating endocrine disorders
GB9626324D0 (en) Process
HU0000218A3 (en) Methods for improving seeds
PL196157B1 (en) Transaction effecting apparatus
GB9715241D0 (en) Device for treating aneurysms
IL136096D0 (en) Machining apparatus
AU7085100A (en) Method for treating otic disorders
GB0106312D0 (en) Process
GB9826874D0 (en) Process
GB9816385D0 (en) Process
GB9821218D0 (en) Treatment for fabrics
EP0921802A4 (en) Method for treating pain
EP0906104A4 (en) Method for treating pain
HK1016893A1 (en) Agent for treating neurodegenerative disorders

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed